Eagle Pharmaceuticals Inc. (EGRX)

$4.55

-0.06

(-1.3%)▲

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Eagle Pharmaceuticals Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 66.30M → 64.64M (in $), with an average decrease of 2.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 8.16M → 5.16M (in $), with an average decrease of 19.9% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 28.3% return, outperforming this stock by 111.8%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 38.2% return, outperforming this stock by 127.9%

Performance

  • $4.53
    $4.81
    $4.55
    downward going graph

    0.44%

    Downside

    Day's Volatility :5.82%

    Upside

    5.41%

    downward going graph
  • $4.10
    $30.40
    $4.55
    downward going graph

    9.89%

    Downside

    52 Weeks Volatility :86.51%

    Upside

    85.03%

    downward going graph

Returns

PeriodEagle Pharmaceuticals Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-3.81%
-0.4%
0.0%
6 Months
-65.56%
9.6%
0.0%
1 Year
-83.57%
3.9%
-1.3%
3 Years
-89.67%
12.8%
-22.1%

Highlights

Market Capitalization
59.7M
Book Value
$19.25
Earnings Per Share (EPS)
0.85
PE Ratio
5.42
PEG Ratio
0.91
Wall Street Target Price
17.0
Profit Margin
4.64%
Operating Margin TTM
15.94%
Return On Assets TTM
6.63%
Return On Equity TTM
4.88%
Revenue TTM
257.6M
Revenue Per Share TTM
19.68
Quarterly Revenue Growth YOY
-12.8%
Gross Profit TTM
221.7M
EBITDA
62.3M
Diluted Eps TTM
0.85
Quarterly Earnings Growth YOY
-0.87
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
1.05
EPS Estimate Next Quarter
0.93

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Eagle Pharmaceuticals Inc.(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 273.63%

Current $4.55
Target $17.00

Company Financials

FY17Y/Y Change
Revenue
236.7M
↑ 24.92%
Net Income
51.9M
↓ 36.23%
Net Profit Margin
21.94%
↓ 21.05%
FY18Y/Y Change
Revenue
213.3M
↓ 9.88%
Net Income
31.9M
↓ 38.58%
Net Profit Margin
14.96%
↓ 6.98%
FY19Y/Y Change
Revenue
195.9M
↓ 8.17%
Net Income
14.3M
↓ 55.14%
Net Profit Margin
7.31%
↓ 7.65%
FY20Y/Y Change
Revenue
187.8M
↓ 4.13%
Net Income
12.0M
↓ 16.24%
Net Profit Margin
6.38%
↓ 0.93%
FY21Y/Y Change
Revenue
171.5M
↓ 8.66%
Net Income
-8.6M
↓ 171.96%
Net Profit Margin
-5.03%
↓ 11.41%
FY22Y/Y Change
Revenue
316.6M
↑ 84.56%
Net Income
35.6M
↓ 513.14%
Net Profit Margin
11.26%
↑ 16.29%
Q1 FY22Q/Q Change
Revenue
115.9M
↑ 173.8%
Net Income
44.1M
↓ 811.07%
Net Profit Margin
38.02%
↑ 52.66%
Q2 FY22Q/Q Change
Revenue
74.1M
↓ 36.02%
Net Income
-9.5M
↓ 121.45%
Net Profit Margin
-12.75%
↓ 50.77%
Q3 FY22Q/Q Change
Revenue
65.9M
↓ 11.11%
Net Income
-3.5M
↓ 62.83%
Net Profit Margin
-5.33%
↑ 7.42%
Q4 FY22Q/Q Change
Revenue
60.7M
↓ 7.89%
Net Income
8.2M
↓ 332.42%
Net Profit Margin
13.45%
↑ 18.78%
Q1 FY23Q/Q Change
Revenue
66.3M
↑ 9.24%
Net Income
5.8M
↓ 29.58%
Net Profit Margin
8.67%
↓ 4.78%
Q2 FY23Q/Q Change
Revenue
64.6M
↓ 2.5%
Net Income
5.2M
↓ 10.19%
Net Profit Margin
7.99%
↓ 0.68%
FY17Y/Y Change
Total Assets
270.1M
↑ 26.45%
Total Liabilities
90.9M
↑ 45.83%
FY18Y/Y Change
Total Assets
238.6M
↓ 11.65%
Total Liabilities
77.8M
↓ 14.38%
FY19Y/Y Change
Total Assets
254.6M
↑ 6.69%
Total Liabilities
75.4M
↓ 3.16%
FY20Y/Y Change
Total Assets
253.2M
↓ 0.54%
Total Liabilities
67.2M
↓ 10.88%
FY21Y/Y Change
Total Assets
253.7M
↑ 0.21%
Total Liabilities
77.3M
↑ 15.03%
FY22Y/Y Change
Total Assets
406.2M
↑ 60.07%
Total Liabilities
172.6M
↑ 123.35%
Q1 FY22Q/Q Change
Total Assets
320.2M
↑ 26.18%
Total Liabilities
104.2M
↑ 34.84%
Q2 FY22Q/Q Change
Total Assets
381.8M
↑ 19.24%
Total Liabilities
143.8M
↑ 37.97%
Q3 FY22Q/Q Change
Total Assets
390.1M
↑ 2.18%
Total Liabilities
154.7M
↑ 7.58%
Q4 FY22Q/Q Change
Total Assets
406.2M
↑ 4.13%
Total Liabilities
172.6M
↑ 11.59%
Q1 FY23Q/Q Change
Total Assets
414.2M
↑ 1.97%
Total Liabilities
171.3M
↓ 0.74%
Q2 FY23Q/Q Change
Total Assets
404.8M
↓ 2.26%
Total Liabilities
152.8M
↓ 10.83%
FY17Y/Y Change
Operating Cash Flow
58.9M
↑ 10.74%
Investing Cash Flow
-5.2M
↓ 88.68%
Financing Cash Flow
8.1M
↓ 124.07%
FY18Y/Y Change
Operating Cash Flow
52.4M
↓ 11.09%
Investing Cash Flow
-133.0K
↓ 97.44%
Financing Cash Flow
-88.1M
↓ 1187.33%
FY19Y/Y Change
Operating Cash Flow
56.0M
↑ 6.88%
Investing Cash Flow
-777.0K
↑ 484.21%
Financing Cash Flow
-24.2M
↓ 72.51%
FY20Y/Y Change
Operating Cash Flow
49.5M
↓ 11.59%
Investing Cash Flow
-18.2M
↑ 2248.39%
Financing Cash Flow
-37.9M
↑ 56.33%
FY21Y/Y Change
Operating Cash Flow
28.2M
↓ 42.99%
Investing Cash Flow
-5.3M
↓ 70.83%
Financing Cash Flow
-28.4M
↓ 25.03%
FY22Y/Y Change
Operating Cash Flow
50.7M
↑ 79.67%
Investing Cash Flow
-86.8M
↑ 1531.22%
Financing Cash Flow
-6.2M
↓ 78.13%
Q1 FY22Q/Q Change
Operating Cash Flow
-16.6M
↓ 305.56%
Investing Cash Flow
-168.0K
↑ 242.86%
Financing Cash Flow
-11.4M
↑ 12.3%
Q2 FY22Q/Q Change
Operating Cash Flow
43.0M
↓ 358.82%
Investing Cash Flow
-75.4M
↑ 44790.48%
Financing Cash Flow
-536.0K
↓ 95.28%
Q3 FY22Q/Q Change
Operating Cash Flow
-13.2M
↓ 130.79%
Investing Cash Flow
-11.2M
↓ 85.1%
Financing Cash Flow
3.3M
↓ 714.93%
Q4 FY22Q/Q Change
Operating Cash Flow
37.6M
↓ 383.73%
Investing Cash Flow
-9.0K
↓ 99.92%
Financing Cash Flow
2.4M
↓ 27.52%
Q1 FY23Q/Q Change
Operating Cash Flow
-33.5M
↓ 189.23%
Investing Cash Flow
-12.6M
↑ 139433.33%
Financing Cash Flow
12.6M
↑ 429.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-126.0K
↓ 99.62%
Investing Cash Flow
-6.0K
↓ 99.95%
Financing Cash Flow
-6.4M
↓ 150.7%

Technicals Summary

Sell

Neutral

Buy

Eagle Pharmaceuticals Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
-10.43%
-65.56%
-83.57%
-89.67%
-91.26%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-4.7%
23.86%
29.07%
38.18%
65.61%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.83%
1.09%
-6.49%
12.82%
12.82%
Zoetis Inc.
Zoetis Inc.
-13.27%
-12.59%
-17.47%
-14.66%
42.73%
Viatris Inc.
Viatris Inc.
-4.9%
26.12%
20.58%
-15.79%
-31.15%
Catalent, Inc.
Catalent, Inc.
-0.62%
32.76%
24.72%
-51.21%
26.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
5.42
5.42
0.91
0.0
0.05
0.07
NA
19.25
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
53.44
53.44
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.36
29.36
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
28.82
28.82
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
222.4
222.4
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
Buy
$59.7M
-91.26%
5.42
4.64%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.3B
65.61%
53.44
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.5B
12.82%
29.36
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$66.8B
42.73%
28.82
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.2B
-31.15%
222.4
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.0B
26.1%
211.02
-31.77%

Institutional Holdings

  • BlackRock Inc

    7.60%

  • HHG PLC

    5.98%

  • Brandes Investment Partners & Co

    5.75%

  • Vanguard Group Inc

    4.92%

  • Millennium Management LLC

    4.03%

  • AQR Capital Management LLC

    3.81%

Company Information

specialty pharmaceutical company

Organization
Eagle Pharmaceuticals Inc.
Employees
134
CEO
Mr. Michael Graves
Industry
Health Technology

Discover More

FAQs